WEST PHARMACEUTICAL SERVICES INC Form SC 13G/A February 05, 2004

> SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

> > SCHEDULE 13G (Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)*

West Pharmaceutical Services Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

955306-105

(CUSIP Number)

December 31, 2003

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[X] Rule 13d-1(b) [_] Rule 13d-(c) [_] Rule 13d-1(d)

* The remainder of this cove

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 955306-105

1. NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Wilmington Trust Corporation

2.	CHECK THE APP (a) [X] (b) [_]	ROPRIATE BO	X IF A MEMBER	OF A GROUP*			
3.	SEC USE ONLY						
	CITIZENSHIP O	oration					
NU			. SOLE VOTING POWER		439,620		
SHARES BENEFICIALLY OWNED BY		6. SHARE	D VOTING POWE	450,298			
ΕA	СН	7. SOLE	DISPOSITIVE P	OWER	439,620		
ΡE	WITH:		D DISPOSITIVE		450,298		
		UNT BENEFIC		Y EACH REPORTING	PERSON		
10.		THE AGGREGA	TE AMOUNT IN	ROW (9) EXCLUDES	CERTAIN		
11.	PERCENT OF CL	ASS REPRESE	NTED BY AMOUN	T IN ROW (9)			
		6.1%					
	TYPE OF REPOR						
	HC						
CUS	IP No. 95530	6-105					
	NAME OF REPOR		с				
1.	I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)						
	Wilmington Trust Company						
 2							
	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [X] (b) [_]						
3.	SEC USE ONLY						
4.	CITIZENSHIP O						
	Delaware bank	ing corpora	tion				
NUM	BER OF	5. SOLE	VOTING POWER		439,620		

REPORTING		6. SHAREI	445,400					
		7. SOLE I	439,620					
		8. SHAREI	445,400					
9.	AGGREGATE AMO	UNT BENEFIC	IALLY OWNED BY EACH REP	ORTING PERSON				
	885,020							
10.	CHECK BOX IF SHARES* [_]		FE AMOUNT IN ROW (9) EX	CLUDES CERTAIN				
11.	PERCENT OF CL	ASS REPRESEN	NTED BY AMOUNT IN ROW (9)				
	6.1%							
12.	TYPE OF REPOR	TING PERSON'	*					
		BK						
CUS	IP No. 95	5306-105						
1.	NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)							
	Wilmington Trust FSB							
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [X] (b) [_]							
3.	SEC USE ONLY							
4.	CITIZENSHIP O							
	Federal	Savings Bank	¢					
	BER OF	5. SOLE V	JOTING POWER	0				
	EFICIALLY	6. SHAREI	O VOTING POWER	4,898				
EACH	ED BY H	7. SOLE I	DISPOSITIVE POWER	0				
REPO PERS WITH		8. SHAREI	D DISPOSITIVE POWER	4,898				
9.	AGGREGATE AMO	UNT BENEFIC	IALLY OWNED BY EACH REP	ORTING PERSON				
	4,898							
10.	CHECK BOX IF SHARES* [_]		IE AMOUNT IN ROW (9) EX	CLUDES CERTAIN				

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

0% _____ 12. TYPE OF REPORTING PERSON* BK _____ CUSIP No. 955306-105 _____ _____ Item 1(a). Name of Issuer: West Pharmaceutical Services Inc. _____ Item 1(b). Address of Issuer's Principal Executive Offices: 101 Gordon Drive Lionville, PA 19341-0645 _____ Item 2(a). Name of Person Filing: Wilmington Trust Corporation, Wilmington Trust Company and Wilmington Trust FSB _____ Item 2(b). Address of Principal Business Office, or if None, Residence: 1100 North Market Street Wilmington, DE 19890 _____ Item 2(c). Citizenship: Wilmington Trust Corporation is a Delaware corporation; Wilmington Trust Company is a Delaware banking corporation; and Wilmington Trust FSB is a Federal Savings Bank. _____ _____ Item 2(d). Title of Class of Securities: Common Stock _____ _____ Item 2(e). CUSIP Number: 955306-105 _____ Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: (a) [_] Broker or dealer registered under Section 15 of the Exchange Act. (b) [X] Bank as defined in Section 3(a)(6) of the Exchange Act.

Wilmington Trust Company and Wilmington FSB are each Banks and are each direct, wholly- owned subsidiaries of Wilmington Trust Corporation.

- (c) [_] Insurance company as defined in Section 3(a)(19) of the Exchange Act.
- (d) [_] Investment company registered under Section 8 of the Investment Company Act.
- (e) [_] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
- (f) [_] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
- (g) [X] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

Wilmington Trust Corporation is a Parent Holding Company.

- (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
- (i) [_] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
- (j) [X] Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

Wilmington Trust Corporation, Wilmington Trust Company and Wilmington Trust FSB are a Group.

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

- (a) Amount beneficially owned: Wilmington Trust Corporation: 889,918 shares Wilmington Trust Company: 885,020 shares Wilmington Trust FSB: 4,898 shares
- (b) Percent of class:

Wilmington Trust Corporation: 6.1%

CUSIP No. 955306-105

Wilmington	Trust	Company:	6.1%
Wilmington	Trust	FSB:	08

(c) Number of shares as to which Wilmington Trust Corporation has:

(i) Sole power to vote or to direct the vote 439,620 shares

- (ii) Shared power to vote or to direct the vote 450,298 shares
- (iii) Sole power to dispose or to direct the disposition of 439,620

shares (iv) Shared power to dispose or to direct the disposition of 450,298 shares Number of shares as to which Wilmington Trust Company has: (i) Sole power to vote or to direct the vote 439,620 shares (ii) Shared power to vote or to direct the vote 445,400 shares (iii) Sole power to dispose or to direct the disposition of 439,620 shares (iv) Shared power to dispose or to direct the disposition of 445,400 shares Number of shares as to which Wilmington Trust FSB has: (i) Sole power to vote or to direct the vote 0 shares (ii) Shared power to vote or to direct the vote 4,898 shares (iii) Sole power to dispose or to direct the disposition of 0 shares (iv) Shared power to dispose or to direct the disposition of 4,898 shares _____ Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [] _____ Item 6. Ownership of More Than Five Percent on Behalf of Another Person. Not applicable. _____ Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company. Wilmington Trust Company: BK Wilmington Trust FSB: BK CUSIP No. 955306-105 Item 8. Identification and Classification of Members of the Group. Wilmington Trust Corporation: HC Wilmington Trust Company: Wilmington Trust FSB: BK BK _____ Item 9. Notice of Dissolution of Group. Not applicable. _____ Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the

securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a

participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 3, 2004

By: s/Michael A. DiGregorio Michael A. DiGregorio Senior Vice President WILMINGTON TRUST CORPORATION WILMINGTON TRUST COMPANY WILMINGTON TRUST FSB

Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.

Attention. Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001).

WILMINGTON TRUST COMPANY 1100 North Market Street Wilmington, Delaware 19890

February 3, 2004

United States Securities and Exchange Commission 450 Fifth Street, N.W. Washington, D.C. 20549

Dear Gentlemen/Ladies:

Pursuant to Rule 13d-1(b)(1) under the Securities Exchange Act of 1934, as amended, we are filing herewith in electronic format a Schedule 13-G reflecting beneficial ownership as of December 31, 2003 by Wilmington Trust Company, with respect to the following issuer and security:

West Pharmaceutical Services Common Stock

Please contact me if there are any questions regarding this filing.

Sincerely,

/s/ Sharon L. Corbett

Sharon L. Corbett Assistant Vice President and Fiduciary Compliance Counsel

Telephone Number (302) 651-8378